The role of frailty in advanced HF and cardiac transplantation.

Bart, NK; Powell, A; Macdonald, PS

The role of frailty in advanced HF and cardiac transplantation.

Bart, NK Powell, A Macdonald, PS

Permalink

Publisher:: Frontiers
Publication Type:: Journal Article
Citation:: Front Cardiovasc Med, 2023, 10, pp. 1082371
Issue Date:: 2023

Open Access

Copyright Clearance Process

Recently Added
In Progress
Open Access

This item is open access.

Adobe PDF

Download Published versionAdobe PDF (819.97 kB)

View on publisher's site

View statistics

Full metadata record

Field	Value	Language
dc.contributor.author	Bart, NK
dc.contributor.author	Powell, A
dc.contributor.author	Macdonald, PS
dc.date.accessioned	2024-04-08T05:50:47Z
dc.date.available	2023-03-14
dc.date.available	2024-04-08T05:50:47Z
dc.date.issued	2023
dc.identifier.citation	Front Cardiovasc Med, 2023, 10, pp. 1082371
dc.identifier.issn	2297-055X
dc.identifier.issn	2297-055X
dc.identifier.uri	http://hdl.handle.net/10453/177559
dc.description.abstract	Frailty is a complex, multi-system condition often associated with multimorbidity. It has become an important prognostic maker across a range of conditions and is particularly relevant in patients with cardiovascular disease. Frailty encompasses a range of domains including, physical, psychological, and social. There are currently a range of validated tools available to measure frailty. It is an especially important measurement in advanced HF, because frailty occurs in up to 50% of HF patients and is potentially reversible with therapies such as mechanical circulatory support and transplantation. Moreover, frailty is dynamic, and therefore serial measurements are important. This review delves into the measurement of frailty, mechanisms, and its role in different cardiovascular cohorts. Understanding frailty will help determine patients that will benefit from therapies, as well as prognosticate outcomes.
dc.format	Electronic-eCollection
dc.language	eng
dc.publisher	Frontiers
dc.relation.ispartof	Front Cardiovasc Med
dc.relation.isbasedon	10.3389/fcvm.2023.1082371
dc.rights	info:eu-repo/semantics/openAccess
dc.subject.classification	3201 Cardiovascular medicine and haematology
dc.title	The role of frailty in advanced HF and cardiac transplantation.
dc.type	Journal Article
utslib.citation.volume	10
utslib.location.activity	Switzerland
pubs.organisational-group	University of Technology Sydney
pubs.organisational-group	University of Technology Sydney/Faculty of Health
utslib.copyright.status	open_access	*
dc.date.updated	2024-04-08T05:50:44Z
pubs.publication-status	Published online
pubs.volume	10

Abstract:

Frailty is a complex, multi-system condition often associated with multimorbidity. It has become an important prognostic maker across a range of conditions and is particularly relevant in patients with cardiovascular disease. Frailty encompasses a range of domains including, physical, psychological, and social. There are currently a range of validated tools available to measure frailty. It is an especially important measurement in advanced HF, because frailty occurs in up to 50% of HF patients and is potentially reversible with therapies such as mechanical circulatory support and transplantation. Moreover, frailty is dynamic, and therefore serial measurements are important. This review delves into the measurement of frailty, mechanisms, and its role in different cardiovascular cohorts. Understanding frailty will help determine patients that will benefit from therapies, as well as prognosticate outcomes.

Please use this identifier to cite or link to this item:

http://hdl.handle.net/10453/177559